Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864009 | 0.78 | PIK3CD (0.41) | PIK3CDDHFRNR4A2 | |
| SCHEMBL22304003 | 0.74 | PIK3CD (0.42) | PIK3CDNR4A2 | |
| Hydrochloric Acid SCHEMBL863977 | 0.72 | LMNA (0.49) | PIK3CDNR4A2 | |
| Hydrochloric Acid SCHEMBL863976 | 0.72 | LMNA (0.49) | PIK3CDNR4A2 | |
| SCHEMBL864265 | 0.70 | CDK1 (0.52) | PIK3CD | |
| SCHEMBL15184821 | 0.70 | PIK3CD (0.50) | PIK3CDEGFRKDR | |
| SCHEMBL863354 | 0.67 | PIK3CD (0.42) | PIK3CDEGFRKDRNR4A2 | |
| SCHEMBL15184789 | 0.67 | PIK3CD (0.49) | PIK3CDKDR | |
| SCHEMBL4177989 | 0.65 | PIK3CD (0.44) | PIK3CDEGFRKDR | |
| SCHEMBL10251857 | 0.65 | PIK3CD (0.44) | PIK3CDNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885DHFR 1615/4885EGFR 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.